S1166 |
Cisplatin
|
シスプラチン (Cisplatin (NSC 119875, Cisplatinum, cis-diamminedichloroplatinum II, CDDP, cis DDP, DDP)) は無機白金錯体であり、腫瘍細胞中において DNA 付加物を形成することにより DNA 合成を阻害する能力を有します。シスプラチンはフェロトーシス (ferroptosis) を活性化し、オートファジー (autophagy) を誘導します。溶液は都度調製してください。DMSO is not recommended to dissolve platinum-based drugs, which can easily lead to drug inactivation.Solutions are unstable and should be fresh-prepared. |
-
Nat Commun, 2024, 15(1):866
-
Clin Cancer Res, 2024, 30(1):187-197
-
Cancer Lett, 2024, 586:216695
|
|
S7397 |
Sorafenib
|
Sorafenib is a multikinase inhibitor of Raf-1 and B-Raf with IC50 of 6 nM and 22 nM in cell-free assays, respectively. Sorafenib inhibits VEGFR-2, VEGFR-3, PDGFR-β, Flt-3 and c-KIT with IC50 of 90 nM, 20 nM, 57 nM, 59 nM and 68 nM, respectively. Sorafenib induces autophagy and apoptosis and activates ferroptosis with anti-tumor activity. |
-
Genomics, 2024, 116(1):110764
-
Mol Cell, 2023, 83(5):803-818.e8
-
Adv Sci (Weinh), 2023, 10.1002/advs.202302025
|
|
S2111 |
Lapatinib
|
Lapatinib, used in the form of Lapatinib Ditosylate, is a potent EGFR and ErbB2 inhibitor with IC50 of 10.8 and 9.2 nM in cell-free assays, respectively. Lapatinib induces ferroptosis and autophagic cell death. |
-
Drug Resist Updat, 2024, 73:101066
-
Nat Commun, 2023, 14(1):5035
-
Nat Commun, 2023, 10.1038/s41467-023-39059-3
|
|
S7243 |
Fer-1 (Ferrostatin-1)
|
Fer-1 (Ferrostatin-1) is a potent and selective inhibitor of ferroptosis with EC50 of 60 nM. |
-
Nature, 2024, 626(7998):411-418.
-
Redox Biol, 2024, 70:103067
-
Redox Biol, 2024, 69:103002
|
|
S7242 |
Erastin
|
Erastin is a ferroptosis activator by acting on mitochondrial VDAC, exhibiting selectivity for tumor cells bearing oncogenic RAS. Solutions are unstable and should be fresh-prepared. |
-
Nat Commun, 2024, 15(1):1429
-
Genome Biol, 2024, 25(1):58
-
Redox Biol, 2024, 69:103002
|
|
S8155 |
RSL3
|
RSL3 ((1S,3R)-RSL3) is a ferroptosis activator in a VDAC-independent manner,exhibiting selectivity for tumor cells bearing oncogenic RAS. RSL3 binds, inactivates GPX4 and thus mediates GPX4-regulated ferroptosis. |
-
Nature, 2024, 626(7998):411-418.
-
Nat Commun, 2024, 15(1):1429
-
Biomed Pharmacother, 2024, 171:116163
|
|
S1040 |
Sorafenib tosylate
|
Sorafenib tosylate is a multikinase inhibitor of Raf-1 and B-Raf with IC50 of 6 nM and 22 nM in cell-free assays, respectively. Sorafenib Tosylate inhibits VEGFR-2, VEGFR-3, PDGFR-β, Flt-3 and c-KIT with IC50 of 90 nM, 20 nM, 57 nM, 59 nM and 68 nM, respectively. Sorafenib Tosylate induces autophagy and apoptosis and activates ferroptosis with anti-tumor activity. |
-
bioRxiv, 2024, 10.1101/2023.01.18.524628
-
Cell, 2023, S0092-8674(23)01032-2
-
Cell Rep Med, 2023, 10.1016/j.xcrm.2023.101286
|
|
S7699 |
Liproxstatin-1
|
Liproxstatin-1 is a potent ferroptosis inhibitor with an IC50 of 22 nM. |
-
Nature, 2024, 626(7998):411-418.
-
Nat Commun, 2024, 15(1):1429
-
J Transl Med, 2024, 22(1):9
|
|
S1077 |
SB202190
|
SB202190 is a potent p38 MAPK inhibitor targeting p38α/β with IC50 of 50 nM/100 nM in cell-free assays, sometimes used instead of SB 203580 to investigate potential roles for SAPK2a/p38 in vivo. SB202190 inhibits endothelial cell apoptosis via induction of autophagy and heme oxygenase-1. SB202190 significantly suppresses Erastin‐dependent ferroptosis. |
-
Cell Rep Med, 2024, 5(2):101396
-
Theranostics, 2024, 14(4):1561-1582
-
Clin Transl Med, 2024, 14(2):e1583
|
|
S1623 |
Acetylcysteine (N-acetylcysteine)
|
Acetylcysteine (N-acetyl-l-cysteine, NAC,N-acetylcysteine) is a ROS(reactive oxygen species) inhibitor that antagonizes the activity of proteasome inhibitors. It is also a tumor necrosis factor production inhibitor. Acetylcysteine(N-acetyl-l-cysteine) suppresses TNF-induced NF-κB activation through inhibition of IκB kinases. Acetylcysteine(N-acetyl-l-cysteine) induces apoptosis via the mitochondria-dependent pathway. Acetylcysteine(N-acetyl-l-cysteine) inhibits ferroptosis and virus replication.Solutions are unstable and should be fresh-prepared. |
-
Cell Signal, 2024, 114:111004
-
Korean J Physiol Pharmacol, 2024, 28(1):21-30
-
Sci Adv, 2024, 10(3):eadi2012
|
|
S8790 |
ML385
|
ML385 is a novel and specific NRF2 inhibitor with an IC50 of 1.9 μM. It inhibits the downstream target gene expression of NRF2. NRF2 regulates the activity of several ferroptosis and lipid peroxidation-related proteins. |
-
Cell Death Discov, 2024, 10(1):35
-
J Cell Mol Med, 2024, 28(2):e18055
-
Nat Commun, 2023, 14(1):6107
|
|
S1007 |
Roxadustat (FG-4592)
|
Roxadustat (FG-4592) is an HIF-α prolyl hydroxylase inhibitor in a cell-free assay, stabilizes HIF-2 and induces EPO production. Roxadustat potentiates RSL3 induced ferroptosis. Phase 3. |
-
Cell Rep, 2024, 43(1):113606.
-
PLoS Pathog, 2024, 20(1):e1011917
-
Signal Transduct Target Ther, 2023, 10.1038/s41392-023-01578-2
|
|
S5742 |
Deferoxamine mesylate
|
Deferoxamine mesylate is the mesylate salt of Deferoxamine, which forms iron complexes and is used as a chelating agent. Deferoxamine is a ferroptosis inhibitor that stabilizes HIF-1α expression and improves HIF-1α transactivity in hypoxic and hyperglycemic states in vitro. Deferoxamine decreases beta-amyloid (Aβ) deposition and induces autophagy.Please do not prepare stock solutions with normal saline or PBS, as precipitation may occur. |
-
Redox Biol, 2024, 69:103008
-
Ecotoxicol Environ Saf, 2024, 270:115889
-
J Cancer, 2024, 15(3):685-698
|
|
S1792 |
Simvastatin
|
Simvastatin is a competitive inhibitor of HMG-CoA reductase with Ki of 0.1-0.2 nM in cell-free assays. Simvastatin induces ferroptosis, mitophagy, autophagy and apoptosis. |
-
Neuron, 2023, S0896-6273(23)00513-5
-
Cancer Res, 2023, 83(13):2248-2261
-
Cell Death Dis, 2023, 14(4):234
|
|
S2556 |
Rosiglitazone
|
Rosiglitazone is a potent antihyperglycemic agent and a potent thiazolidinedione insulin sensitizer with IC50 of 12, 4 and 9 nM for rat, 3T3-L1 and human adipocytes, respectively. Rosiglitazone is a pure ligand of PPAR-gamma, and has no PPAR-alpha-binding action. Rosiglitazone modulates TRP channels and induces autophagy. Rosiglitazone prevents ferroptosis. |
-
Nat Commun, 2024, 15(1):1429
-
Metabolites, 2024, 14(1)64
-
J Hematol Oncol, 2023, 16(1):30
|
|
S7171 |
Setanaxib (GKT137831)
|
Setanaxib (GKT137831, GKT831) is a potent, dual NADPH oxidase NOX1/NOX4 inhibitor with Ki of 110 nM and 140 nM, respectively. Treatment with GKT137831 suppresses reactive oxygen species (ROS) production. GKT137831 partly inhibits ferroptosis. |
-
Immunity, 2024, 57(1):52-67.e10
-
Biomed Pharmacother, 2024, 170:116042
-
Nat Commun, 2023, 14(1):1235
|
|
S7309 |
BAY 87-2243
|
BAY 87-2243 is a potent and selective hypoxia-inducible factor-1 (HIF-1) inhibitor. BAY 87-2243 inhibits mitochondrial complex I activity, thus triggering a mitophagy-dependent ROS increase leading to necroptosis and ferroptosis. BAY 87-2243 exerts antitumor activity. Phase 1. |
-
Mol Ther Nucleic Acids, 2023, 31:421-436
-
Mol Med, 2023, 29(1):91
-
Biomater Res, 2023, 27(1):11
|
|
S1848 |
Curcumin
|
Curcumin (Diferuloylmethane, Natural Yellow 3, Turmeric yellow) is the principal curcuminoid of the popular Indian spice turmeric, which is a member of the ginger family (Zingiberaceae). It is an inhibitor of p300 histone acetylatransferase(IC50~25 μM)and Histone deacetylase (HDAC); activates Nrf2 pathway and supresses the activation of NF-κB. Curcumin induces mitophagy, autophagy, apoptosis, and cell cycle arrest with antitumor activity. Curcumin reduces renal damage associated with rhabdomyolysis by decreasing ferroptosis-mediated cell death. Curcumin exhibits anti-infective properties against various human pathogens like the influenza virus, hepatitis C virus, HIV and so on. |
-
Nutrients, 2023, 15(3)740
-
Phytother Res, 2022, 36(3):1326-1337
-
Oncol Rep, 2022, 48(6)221
|
|
S8661 |
CA3 (CIL56)
|
CA3 (CIL56) has potent inhibitory effects on YAP1/Tead transcriptional activity and primarily targets YAP1 high and therapy-resistant esophageal adenocarcinoma cells endowed with CSC properties. CA3(CIL56) induces ferroptosis and iron-dependent reactive oxygen species (ROS). |
-
Nat Commun, 2023, 14(1):6699
-
EMBO Mol Med, 2023, e17187.
-
Int J Nanomedicine, 2023, 18:2989-3006
|
|
S8078 |
Bardoxolone Methyl
|
Bardoxolone Methyl (RTA 402, TP-155, NSC 713200, CDDO Methyl Ester, CDDO-Me) is an IKK inhibitor, showing potent proapoptotic and anti-inflammatory activities; Also a potent Nrf2 activator and nuclear factor-κB (NF-κB) inhibitor. Bardoxolone Methyl abrogates ferroptosis. Bardoxolone methyl induces apoptosis and autophagy in cancer cells. |
-
Nat Commun, 2023, 14(1):3648
-
Redox Biol, 2023, 60:102632
-
Cell Rep, 2023, 42(12):113431
|
|
S2505 |
Rosiglitazone maleate
|
Rosiglitazone maleate, a member of the thiazolidinedione class of antihyperglycaemic agents, is a high-affinity selective agonist of the peroxisome proliferator-activated receptor-γ (PPAR-γ) with IC50 of 42 nM. Rosiglitazone maleate also modulates TRP channels and induces autophagy. Rosiglitazone prevents ferroptosis. |
-
Stem Cell Reports, 2022, 17(11):2531-2547
-
Cell Death Dis, 2021, 12(11):972
-
Antioxidants (Basel), 2021, 10(2)155
|
|
S8254 |
FIN56
|
FIN56 is a specific inducer of ferroptosis . |
-
Antioxidants (Basel), 2024, 13(1)114
-
J Hematol Oncol, 2023, 16(1):46
-
Exp Hematol Oncol, 2023, 12(1):47
|
|
S8877New |
IKE(Imidazole ketone erastin)
|
IKE(Imidazole ketone erastin) is a potent, selective, and metabolically stable system xc– inhibitor and inducer of ferroptosis. |
-
Cell Death Dis, 2024, 15(1):79
-
Nat Commun, 2023, 14(1):4758
-
Nat Commun, 2023, 14(1):4758
|
|
S3031 |
Linagliptin (GSK2118436)
|
Linagliptin (GSK2118436) is a highly potent, selective DPP-4 inhibitor with IC50 of 1 nM and exhibits a 10,000-fold higher selectivity for DPP-4 than for other dipeptidyl peptidases such as DPP-2, DPP-8, and DPP-9. Linagliptin activates glomerular autophagy in a model of type 2 diabetes. DPP4 mediates ferroptosis in TP53-deficient CRC cells. |
-
Cell Death Dis, 2023, 10.1038/s41419-023-06240-x
-
J Pers Med, 2022, 12(2)258
-
Hum Cell, 2022, 10.1007/s13577-022-00671-y
|
|
S1576 |
Sulfasalazine
|
Sulfasalazine is a sulfa derivative of mesalazine, used as an anti-inflammatory agent to treat bowel disease and rheumatoid arthritis. Sulfasalazine is a potent and specific inhibitor of nuclear factor kappa B (NF-κB), TGF-β and COX-2. Sulfasalazine induces ferroptosis, apoptosis and autophagy. |
-
Adv Sci (Weinh), 2023, 10(20):e2300517
-
Proc Natl Acad Sci U S A, 2022, 119(36):e2117396119
-
Cell Mol Life Sci, 2022, 79(5):228
|
|
S1712 |
Deferasirox
|
Deferasirox is an iron chelator, also a cytochrome P450 3A4 inducer, Cytochrome P450 2C8 inhibitor, and Cytochrome P450 1A2 inhibitor. Deferasirox-induced iron depletion promotes BclxL downregulation and cell death. |
-
Elife, 2023, 12RP88745
-
J Transl Med, 2023, 21(1):50
-
Cell Death Discov, 2023, 9(1):97
|
|
S2046 |
Pioglitazone HCl
|
Pioglitazone HCl (AD-4833, U-72107E) is an inhibitor of cytochrome P450 (CYP)2C8 and CYP3A4 enzymes. Pioglitazone HCl inhibits CYP2C8, CYP3A4 and CYP2C9 with Ki of 1.7 μM, 11.8 μM and 32.1 μM, respectively. Pioglitazone HCl is also a selective peroxisome proliferator-activated receptor-gamma (PPARγ) agonist with EC50 of 0.93 μM and 0.99 μM for human PPARγ and mouse PPARγ, respectively. Pioglitazone HCl inhibits mitochondrial iron uptake, lipid peroxidation, and subsequent ferroptosis. |
-
Commun Biol, 2022, 5(1):231
-
J Genet Genomics, 2022, S1673-8527(22)00133-3
-
J Cell Mol Med, 2022, 10.1111/jcmm.17154
|
|
S1443 |
Zileuton
|
Zileuton is an orally active inhibitor of 5-lipoxygenase, and thus inhibits leukotrienes (LTB4, LTC4, LTD4, and LTE4) formation, used to decrease the symptoms of asthma. Zileuton induces apoptosis while inhibits ferroptosis. |
-
J Transl Med, 2023, 21(1):923
-
Cancer Sci, 2023, 10.1111/cas.15994
-
Biomol Ther (Seoul), 2023, 10.4062/biomolther.2023.062
|
|
S8792 |
UAMC-3203
|
UAMC-3203 is an improved ferroptosis inhibitor with an IC50 value of 10 nM in IMR-32 Neuroblastoma Cells. |
-
Cell Death Differ, 2023, 30(8):1988-2004
-
Br J Cancer, 2023, 129(4):601-611
-
Br J Cancer, 2023, 129(4):601-611
|
|
S0788 |
ML 210
|
ML-210 (CID 49766530) is a selective covalent inhibitor of cellular glutathione peroxidase 4 (GPX4) with EC50 of 0.04 μM and induces ferroptosis. ML-210 can selectively kill cells induced to express mutant RAS. ML-210 exhibits anti-cancer activity. |
-
Sci Adv, 2024, 10(7):eadk1835
-
Redox Biol, 2023, 62:102678
-
Redox Biology, 2023, Volume 62
|
|
S8432 |
Troglitazone
|
Troglitazone is a potent agonist for the peroxisome proliferator-activated receptor-(PPAR) that is a ligand activated transcription factor regulating cell differentiation and growth. Troglitazone induces autophagy, apoptosis and necroptosis in bladder cancer cells. Troglitazone prevents RSL3-induced ferroptosis and lipid peroxidation in Pfa1 cells. |
-
Free Radic Biol Med, 2021, 163:234-242
-
Biomed Pharmacother, 2020, 132:110741
-
Nat Commun, 2019, 11;10(1):4621
|
|
S4452 |
ML162
|
ML162 is a covalent inhibitor of cellular phospholipid glutathione peroxidase (GPX-4) that induces ferroptosis. |
-
Sci Adv, 2024, 10(7):eadk1835
-
Int J Mol Sci, 2023, 24(2)1667
-
Cell Metab, 2022, S1550-4131-2200411-9
|
|
S9663 |
iFSP1
|
iFSP1 is a potent, selective and glutathione-independent inhibitor of ferroptosis suppressor protein 1 (FSP1/AIFM2) with EC50 of 103 nM. iFSP1 selectively induces ferroptosis in GPX4-knockout Pfa1 and HT1080 cells that overexpresses FSP1.Solutions are unstable and should be fresh-prepared. |
-
bioRxiv, 2023, 10.1101/2023.04.05.535746
|
|
E0375 |
Ammonium ferric citrate
|
Ammonium ferric citrate (Ferric ammonium citrate, Ammonium iron(III) citrate, Iron ammonium citrate, FerriSeltz) induces ferroptosis in non-small-cell lung carcinoma through the inhibition of GPX4-GSS/GSR-GGT axis activity.
|
-
Cell Death Discov, 2023, 10.1038/s41420-023-01712-7
|
|
S9840 |
SRS16-86
|
SRS16-86, a novel third-generation ferrostatin, is an inhibitor of ferroptosis. |
-
Chem Biol Interact, 2022, 369:110262
|
|
S9839 |
SRS11-92
|
SRS11-92 (AA9), a Ferrostatin-1 (Fer-1) analogue, is a potent inhibitor of ferroptosis. SRS11-92 inhibits ferroptotic cell death induced by Erastin in HT-1080 human fibrosarcoma cells with EC50 of 6 nM. |
-
CNS Neurosci Ther, 2023, 10.1111/cns.14130
|
|
S3984 |
Nordihydroguaiaretic acid (NDGA)
|
Nordihydroguaiaretic acid (NDGA) is a phenolic antioxidant found in the leaves and twigs of the evergreen desert shrub, Larrea tridentata (Sesse and Moc. ex DC) Coville (creosote bush). It is a recognized inhibitor of lipoxygenase (LOX) and has antioxidant and free radical scavenging properties. Nordihydroguaiaretic acid (NDGA) is a cytotoxic insulin-like growth factor-I receptor (IGF-1R)/HER2 inhibitor and induces apoptosis. Nordihydroguaiaretic acid (NDGA) inhibits p300 and activates autophagy. Nordihydroguaiaretic acid (NDGA) protects cells from ferroptosis. |
|
|
E1063 |
Piperazine Erastin
|
Piperazine Erastin is an analog of Erastin, which can induces ferroptosis in cancer cells, an iron-dependent form of nonapoptotic cell death. |
|
|
E1874New |
Erastin2
|
Erastin2 is an inducer of ferroptosis. It also selectively inhibits xc(-) cystine/glutamate transporter. It induces ferroptosis in HT-1080, T98G, and A549 cells with the potential to treat neurodegenerative diseases. |
|
|
E1574New |
FSEN1
|
FSEN1 is a potent and non-competitive FSP1 inhibitor with an IC50 value of 313 nM. It triggers iron death in cancer cells by inhibiting FSP1 and can be used in research of cancer. |
|
|
E1812New |
N6F11
|
N6F11 is an inducer of ferroptosis. N6F11 is bound to the RING domain of the E3 ubiquitin ligase tripartite motif containing 25 (TRIM25) in cancer cells to trigger TRIM25-mediated K48-linked ubiquitination of glutathione peroxidase 4 (GPX4), resulting in proteasomal degradation. |
|
|
S7243 |
Fer-1 (Ferrostatin-1)
|
Fer-1 (Ferrostatin-1) is a potent and selective inhibitor of ferroptosis with EC50 of 60 nM. |
- Nature, 2024, 626(7998):411-418.
- Redox Biol, 2024, 70:103067
- Redox Biol, 2024, 69:103002
|
|
S7699 |
Liproxstatin-1
|
Liproxstatin-1 is a potent ferroptosis inhibitor with an IC50 of 22 nM. |
- Nature, 2024, 626(7998):411-418.
- Nat Commun, 2024, 15(1):1429
- J Transl Med, 2024, 22(1):9
|
|
S1077 |
SB202190
|
SB202190 is a potent p38 MAPK inhibitor targeting p38α/β with IC50 of 50 nM/100 nM in cell-free assays, sometimes used instead of SB 203580 to investigate potential roles for SAPK2a/p38 in vivo. SB202190 inhibits endothelial cell apoptosis via induction of autophagy and heme oxygenase-1. SB202190 significantly suppresses Erastin‐dependent ferroptosis. |
- Cell Rep Med, 2024, 5(2):101396
- Theranostics, 2024, 14(4):1561-1582
- Clin Transl Med, 2024, 14(2):e1583
|
|
S1623 |
Acetylcysteine (N-acetylcysteine)
|
Acetylcysteine (N-acetyl-l-cysteine, NAC,N-acetylcysteine) is a ROS(reactive oxygen species) inhibitor that antagonizes the activity of proteasome inhibitors. It is also a tumor necrosis factor production inhibitor. Acetylcysteine(N-acetyl-l-cysteine) suppresses TNF-induced NF-κB activation through inhibition of IκB kinases. Acetylcysteine(N-acetyl-l-cysteine) induces apoptosis via the mitochondria-dependent pathway. Acetylcysteine(N-acetyl-l-cysteine) inhibits ferroptosis and virus replication.Solutions are unstable and should be fresh-prepared. |
- Cell Signal, 2024, 114:111004
- Korean J Physiol Pharmacol, 2024, 28(1):21-30
- Sci Adv, 2024, 10(3):eadi2012
|
|
S5742 |
Deferoxamine mesylate
|
Deferoxamine mesylate is the mesylate salt of Deferoxamine, which forms iron complexes and is used as a chelating agent. Deferoxamine is a ferroptosis inhibitor that stabilizes HIF-1α expression and improves HIF-1α transactivity in hypoxic and hyperglycemic states in vitro. Deferoxamine decreases beta-amyloid (Aβ) deposition and induces autophagy.Please do not prepare stock solutions with normal saline or PBS, as precipitation may occur. |
- Redox Biol, 2024, 69:103008
- Ecotoxicol Environ Saf, 2024, 270:115889
- J Cancer, 2024, 15(3):685-698
|
|
S2556 |
Rosiglitazone
|
Rosiglitazone is a potent antihyperglycemic agent and a potent thiazolidinedione insulin sensitizer with IC50 of 12, 4 and 9 nM for rat, 3T3-L1 and human adipocytes, respectively. Rosiglitazone is a pure ligand of PPAR-gamma, and has no PPAR-alpha-binding action. Rosiglitazone modulates TRP channels and induces autophagy. Rosiglitazone prevents ferroptosis. |
- Nat Commun, 2024, 15(1):1429
- Metabolites, 2024, 14(1)64
- J Hematol Oncol, 2023, 16(1):30
|
|
S7171 |
Setanaxib (GKT137831)
|
Setanaxib (GKT137831, GKT831) is a potent, dual NADPH oxidase NOX1/NOX4 inhibitor with Ki of 110 nM and 140 nM, respectively. Treatment with GKT137831 suppresses reactive oxygen species (ROS) production. GKT137831 partly inhibits ferroptosis. |
- Immunity, 2024, 57(1):52-67.e10
- Biomed Pharmacother, 2024, 170:116042
- Nat Commun, 2023, 14(1):1235
|
|
S1848 |
Curcumin
|
Curcumin (Diferuloylmethane, Natural Yellow 3, Turmeric yellow) is the principal curcuminoid of the popular Indian spice turmeric, which is a member of the ginger family (Zingiberaceae). It is an inhibitor of p300 histone acetylatransferase(IC50~25 μM)and Histone deacetylase (HDAC); activates Nrf2 pathway and supresses the activation of NF-κB. Curcumin induces mitophagy, autophagy, apoptosis, and cell cycle arrest with antitumor activity. Curcumin reduces renal damage associated with rhabdomyolysis by decreasing ferroptosis-mediated cell death. Curcumin exhibits anti-infective properties against various human pathogens like the influenza virus, hepatitis C virus, HIV and so on. |
- Nutrients, 2023, 15(3)740
- Phytother Res, 2022, 36(3):1326-1337
- Oncol Rep, 2022, 48(6)221
|
|
S8078 |
Bardoxolone Methyl
|
Bardoxolone Methyl (RTA 402, TP-155, NSC 713200, CDDO Methyl Ester, CDDO-Me) is an IKK inhibitor, showing potent proapoptotic and anti-inflammatory activities; Also a potent Nrf2 activator and nuclear factor-κB (NF-κB) inhibitor. Bardoxolone Methyl abrogates ferroptosis. Bardoxolone methyl induces apoptosis and autophagy in cancer cells. |
- Nat Commun, 2023, 14(1):3648
- Redox Biol, 2023, 60:102632
- Cell Rep, 2023, 42(12):113431
|
|
S2505 |
Rosiglitazone maleate
|
Rosiglitazone maleate, a member of the thiazolidinedione class of antihyperglycaemic agents, is a high-affinity selective agonist of the peroxisome proliferator-activated receptor-γ (PPAR-γ) with IC50 of 42 nM. Rosiglitazone maleate also modulates TRP channels and induces autophagy. Rosiglitazone prevents ferroptosis. |
- Stem Cell Reports, 2022, 17(11):2531-2547
- Cell Death Dis, 2021, 12(11):972
- Antioxidants (Basel), 2021, 10(2)155
|
|
S3031 |
Linagliptin (GSK2118436)
|
Linagliptin (GSK2118436) is a highly potent, selective DPP-4 inhibitor with IC50 of 1 nM and exhibits a 10,000-fold higher selectivity for DPP-4 than for other dipeptidyl peptidases such as DPP-2, DPP-8, and DPP-9. Linagliptin activates glomerular autophagy in a model of type 2 diabetes. DPP4 mediates ferroptosis in TP53-deficient CRC cells. |
- Cell Death Dis, 2023, 10.1038/s41419-023-06240-x
- J Pers Med, 2022, 12(2)258
- Hum Cell, 2022, 10.1007/s13577-022-00671-y
|
|
S2046 |
Pioglitazone HCl
|
Pioglitazone HCl (AD-4833, U-72107E) is an inhibitor of cytochrome P450 (CYP)2C8 and CYP3A4 enzymes. Pioglitazone HCl inhibits CYP2C8, CYP3A4 and CYP2C9 with Ki of 1.7 μM, 11.8 μM and 32.1 μM, respectively. Pioglitazone HCl is also a selective peroxisome proliferator-activated receptor-gamma (PPARγ) agonist with EC50 of 0.93 μM and 0.99 μM for human PPARγ and mouse PPARγ, respectively. Pioglitazone HCl inhibits mitochondrial iron uptake, lipid peroxidation, and subsequent ferroptosis. |
- Commun Biol, 2022, 5(1):231
- J Genet Genomics, 2022, S1673-8527(22)00133-3
- J Cell Mol Med, 2022, 10.1111/jcmm.17154
|
|
S1443 |
Zileuton
|
Zileuton is an orally active inhibitor of 5-lipoxygenase, and thus inhibits leukotrienes (LTB4, LTC4, LTD4, and LTE4) formation, used to decrease the symptoms of asthma. Zileuton induces apoptosis while inhibits ferroptosis. |
- J Transl Med, 2023, 21(1):923
- Cancer Sci, 2023, 10.1111/cas.15994
- Biomol Ther (Seoul), 2023, 10.4062/biomolther.2023.062
|
|
S8792 |
UAMC-3203
|
UAMC-3203 is an improved ferroptosis inhibitor with an IC50 value of 10 nM in IMR-32 Neuroblastoma Cells. |
- Cell Death Differ, 2023, 30(8):1988-2004
- Br J Cancer, 2023, 129(4):601-611
- Br J Cancer, 2023, 129(4):601-611
|
|
S8432 |
Troglitazone
|
Troglitazone is a potent agonist for the peroxisome proliferator-activated receptor-(PPAR) that is a ligand activated transcription factor regulating cell differentiation and growth. Troglitazone induces autophagy, apoptosis and necroptosis in bladder cancer cells. Troglitazone prevents RSL3-induced ferroptosis and lipid peroxidation in Pfa1 cells. |
- Free Radic Biol Med, 2021, 163:234-242
- Biomed Pharmacother, 2020, 132:110741
- Nat Commun, 2019, 11;10(1):4621
|
|
S9840 |
SRS16-86
|
SRS16-86, a novel third-generation ferrostatin, is an inhibitor of ferroptosis. |
- Chem Biol Interact, 2022, 369:110262
|
|
S9839 |
SRS11-92
|
SRS11-92 (AA9), a Ferrostatin-1 (Fer-1) analogue, is a potent inhibitor of ferroptosis. SRS11-92 inhibits ferroptotic cell death induced by Erastin in HT-1080 human fibrosarcoma cells with EC50 of 6 nM. |
- CNS Neurosci Ther, 2023, 10.1111/cns.14130
|
|
S3984 |
Nordihydroguaiaretic acid (NDGA)
|
Nordihydroguaiaretic acid (NDGA) is a phenolic antioxidant found in the leaves and twigs of the evergreen desert shrub, Larrea tridentata (Sesse and Moc. ex DC) Coville (creosote bush). It is a recognized inhibitor of lipoxygenase (LOX) and has antioxidant and free radical scavenging properties. Nordihydroguaiaretic acid (NDGA) is a cytotoxic insulin-like growth factor-I receptor (IGF-1R)/HER2 inhibitor and induces apoptosis. Nordihydroguaiaretic acid (NDGA) inhibits p300 and activates autophagy. Nordihydroguaiaretic acid (NDGA) protects cells from ferroptosis. |
|
|
E1874New |
Erastin2
|
Erastin2 is an inducer of ferroptosis. It also selectively inhibits xc(-) cystine/glutamate transporter. It induces ferroptosis in HT-1080, T98G, and A549 cells with the potential to treat neurodegenerative diseases. |
|
|
E1574New |
FSEN1
|
FSEN1 is a potent and non-competitive FSP1 inhibitor with an IC50 value of 313 nM. It triggers iron death in cancer cells by inhibiting FSP1 and can be used in research of cancer. |
|
|
S1166 |
Cisplatin
|
シスプラチン (Cisplatin (NSC 119875, Cisplatinum, cis-diamminedichloroplatinum II, CDDP, cis DDP, DDP)) は無機白金錯体であり、腫瘍細胞中において DNA 付加物を形成することにより DNA 合成を阻害する能力を有します。シスプラチンはフェロトーシス (ferroptosis) を活性化し、オートファジー (autophagy) を誘導します。溶液は都度調製してください。DMSO is not recommended to dissolve platinum-based drugs, which can easily lead to drug inactivation.Solutions are unstable and should be fresh-prepared. |
- Nat Commun, 2024, 15(1):866
- Clin Cancer Res, 2024, 30(1):187-197
- Cancer Lett, 2024, 586:216695
|
|
S7397 |
Sorafenib
|
Sorafenib is a multikinase inhibitor of Raf-1 and B-Raf with IC50 of 6 nM and 22 nM in cell-free assays, respectively. Sorafenib inhibits VEGFR-2, VEGFR-3, PDGFR-β, Flt-3 and c-KIT with IC50 of 90 nM, 20 nM, 57 nM, 59 nM and 68 nM, respectively. Sorafenib induces autophagy and apoptosis and activates ferroptosis with anti-tumor activity. |
- Genomics, 2024, 116(1):110764
- Mol Cell, 2023, 83(5):803-818.e8
- Adv Sci (Weinh), 2023, 10.1002/advs.202302025
|
|
S2111 |
Lapatinib
|
Lapatinib, used in the form of Lapatinib Ditosylate, is a potent EGFR and ErbB2 inhibitor with IC50 of 10.8 and 9.2 nM in cell-free assays, respectively. Lapatinib induces ferroptosis and autophagic cell death. |
- Drug Resist Updat, 2024, 73:101066
- Nat Commun, 2023, 14(1):5035
- Nat Commun, 2023, 10.1038/s41467-023-39059-3
|
|
S7242 |
Erastin
|
Erastin is a ferroptosis activator by acting on mitochondrial VDAC, exhibiting selectivity for tumor cells bearing oncogenic RAS. Solutions are unstable and should be fresh-prepared. |
- Nat Commun, 2024, 15(1):1429
- Genome Biol, 2024, 25(1):58
- Redox Biol, 2024, 69:103002
|
|
S8155 |
RSL3
|
RSL3 ((1S,3R)-RSL3) is a ferroptosis activator in a VDAC-independent manner,exhibiting selectivity for tumor cells bearing oncogenic RAS. RSL3 binds, inactivates GPX4 and thus mediates GPX4-regulated ferroptosis. |
- Nature, 2024, 626(7998):411-418.
- Nat Commun, 2024, 15(1):1429
- Biomed Pharmacother, 2024, 171:116163
|
|
S1040 |
Sorafenib tosylate
|
Sorafenib tosylate is a multikinase inhibitor of Raf-1 and B-Raf with IC50 of 6 nM and 22 nM in cell-free assays, respectively. Sorafenib Tosylate inhibits VEGFR-2, VEGFR-3, PDGFR-β, Flt-3 and c-KIT with IC50 of 90 nM, 20 nM, 57 nM, 59 nM and 68 nM, respectively. Sorafenib Tosylate induces autophagy and apoptosis and activates ferroptosis with anti-tumor activity. |
- bioRxiv, 2024, 10.1101/2023.01.18.524628
- Cell, 2023, S0092-8674(23)01032-2
- Cell Rep Med, 2023, 10.1016/j.xcrm.2023.101286
|
|
S1007 |
Roxadustat (FG-4592)
|
Roxadustat (FG-4592) is an HIF-α prolyl hydroxylase inhibitor in a cell-free assay, stabilizes HIF-2 and induces EPO production. Roxadustat potentiates RSL3 induced ferroptosis. Phase 3. |
- Cell Rep, 2024, 43(1):113606.
- PLoS Pathog, 2024, 20(1):e1011917
- Signal Transduct Target Ther, 2023, 10.1038/s41392-023-01578-2
|
|
S1792 |
Simvastatin
|
Simvastatin is a competitive inhibitor of HMG-CoA reductase with Ki of 0.1-0.2 nM in cell-free assays. Simvastatin induces ferroptosis, mitophagy, autophagy and apoptosis. |
- Neuron, 2023, S0896-6273(23)00513-5
- Cancer Res, 2023, 83(13):2248-2261
- Cell Death Dis, 2023, 14(4):234
|
|
S7309 |
BAY 87-2243
|
BAY 87-2243 is a potent and selective hypoxia-inducible factor-1 (HIF-1) inhibitor. BAY 87-2243 inhibits mitochondrial complex I activity, thus triggering a mitophagy-dependent ROS increase leading to necroptosis and ferroptosis. BAY 87-2243 exerts antitumor activity. Phase 1. |
- Mol Ther Nucleic Acids, 2023, 31:421-436
- Mol Med, 2023, 29(1):91
- Biomater Res, 2023, 27(1):11
|
|
S8661 |
CA3 (CIL56)
|
CA3 (CIL56) has potent inhibitory effects on YAP1/Tead transcriptional activity and primarily targets YAP1 high and therapy-resistant esophageal adenocarcinoma cells endowed with CSC properties. CA3(CIL56) induces ferroptosis and iron-dependent reactive oxygen species (ROS). |
- Nat Commun, 2023, 14(1):6699
- EMBO Mol Med, 2023, e17187.
- Int J Nanomedicine, 2023, 18:2989-3006
|
|
S8254 |
FIN56
|
FIN56 is a specific inducer of ferroptosis . |
- Antioxidants (Basel), 2024, 13(1)114
- J Hematol Oncol, 2023, 16(1):46
- Exp Hematol Oncol, 2023, 12(1):47
|
|
S1576 |
Sulfasalazine
|
Sulfasalazine is a sulfa derivative of mesalazine, used as an anti-inflammatory agent to treat bowel disease and rheumatoid arthritis. Sulfasalazine is a potent and specific inhibitor of nuclear factor kappa B (NF-κB), TGF-β and COX-2. Sulfasalazine induces ferroptosis, apoptosis and autophagy. |
- Adv Sci (Weinh), 2023, 10(20):e2300517
- Proc Natl Acad Sci U S A, 2022, 119(36):e2117396119
- Cell Mol Life Sci, 2022, 79(5):228
|
|
S1712 |
Deferasirox
|
Deferasirox is an iron chelator, also a cytochrome P450 3A4 inducer, Cytochrome P450 2C8 inhibitor, and Cytochrome P450 1A2 inhibitor. Deferasirox-induced iron depletion promotes BclxL downregulation and cell death. |
- Elife, 2023, 12RP88745
- J Transl Med, 2023, 21(1):50
- Cell Death Discov, 2023, 9(1):97
|
|
S0788 |
ML 210
|
ML-210 (CID 49766530) is a selective covalent inhibitor of cellular glutathione peroxidase 4 (GPX4) with EC50 of 0.04 μM and induces ferroptosis. ML-210 can selectively kill cells induced to express mutant RAS. ML-210 exhibits anti-cancer activity. |
- Sci Adv, 2024, 10(7):eadk1835
- Redox Biol, 2023, 62:102678
- Redox Biology, 2023, Volume 62
|
|
S4452 |
ML162
|
ML162 is a covalent inhibitor of cellular phospholipid glutathione peroxidase (GPX-4) that induces ferroptosis. |
- Sci Adv, 2024, 10(7):eadk1835
- Int J Mol Sci, 2023, 24(2)1667
- Cell Metab, 2022, S1550-4131-2200411-9
|
|
S9663 |
iFSP1
|
iFSP1 is a potent, selective and glutathione-independent inhibitor of ferroptosis suppressor protein 1 (FSP1/AIFM2) with EC50 of 103 nM. iFSP1 selectively induces ferroptosis in GPX4-knockout Pfa1 and HT1080 cells that overexpresses FSP1.Solutions are unstable and should be fresh-prepared. |
- bioRxiv, 2023, 10.1101/2023.04.05.535746
|
|
E0375 |
Ammonium ferric citrate
|
Ammonium ferric citrate (Ferric ammonium citrate, Ammonium iron(III) citrate, Iron ammonium citrate, FerriSeltz) induces ferroptosis in non-small-cell lung carcinoma through the inhibition of GPX4-GSS/GSR-GGT axis activity.
|
- Cell Death Discov, 2023, 10.1038/s41420-023-01712-7
|
|
E1812New |
N6F11
|
N6F11 is an inducer of ferroptosis. N6F11 is bound to the RING domain of the E3 ubiquitin ligase tripartite motif containing 25 (TRIM25) in cancer cells to trigger TRIM25-mediated K48-linked ubiquitination of glutathione peroxidase 4 (GPX4), resulting in proteasomal degradation. |
|
|